{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:54:21Z","timestamp":1761746061500,"version":"3.41.2"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>National Institute for Clinical Excellence (NICE) guidance for the management of neonatal sepsis recommends a first-line antibiotic regimen containing an aminoglycoside (gentamicin). Aminoglycoside exposure causes sensorineural hearing loss in individuals with a specific mitochondrial genetic variant (m.1555A&amp;gt;G). This variant can be detected promptly (in &amp;lt;30\u2005min) by a point of care test. NICE does allow for variation in antibiotic regimes depending on local microbiology guidance. As practices can vary, this survey aimed to determine the current use of first-line antibiotic agents within neonatal units and postnatal wards across the UK.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design and setting<\/jats:title><jats:p>A telephone survey was conducted across all neonatal units in the United Kingdom. Responses were requested from a member of the neonatal team experienced in neonatal septic screening processes. One response was recorded per unit.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 187 neonatal units, 186 (99%) responded to the survey. One unit declined to participate. The survey results show most neonatal units (93%) and postnatal wards (74%) across the United Kingdom use aminoglycosides as first-line antibiotic agents. Antibiotic regimes varied between different units and between different locations within the same hospital (NICU vs. postnatal wards). In cases where there was a contraindication to aminoglycosides, the most common alternative antibiotic was cefotaxime.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Most neonatal units in the UK use an aminoglycoside antibiotic as first-line agent for suspected sepsis. This places infants with the m.1555A&amp;gt;G genetic variant at risk of iatrogenic hearing loss. There needs to be integration of point-of-care genetic testing within the neonatal septic screening pathway.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2024.1471463","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T04:48:07Z","timestamp":1730177287000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A national survey of first line antibiotic use in neonatal units \u2013 and the potential scope for iatrogenic sensorineural hearing loss prevention"],"prefix":"10.3389","volume":"12","author":[{"given":"J.","family":"Peterson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Muddiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Groves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Booth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. G.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. H.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mahaveer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"year":"","article-title":"Neonatal infection: antibiotics for prevention and treatment. NICE guideline [NG195]","key":"B1"},{"key":"B2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1136\/archdischild-2021-322861","article-title":"Effect of antibiotics in the first week of life on faecal microbiota development","volume":"107","author":"Van Daele","year":"2022","journal-title":"Arch Dis Childhood Fetal Neonat Ed"},{"year":"","article-title":"National Tariff Payment System: Non-mandatory guide and benchmark prices. 2022\/2023","key":"B3"},{"key":"B4","doi-asserted-by":"publisher","first-page":"F9","DOI":"10.1136\/adc.2009.178798","article-title":"Neonatal infections in England: the NeonIN surveillance network","volume":"96","author":"Vergnano","year":"2011","journal-title":"Arch Dis Childhood Fetal Neonat Ed"},{"key":"B5","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1159\/000518059","article-title":"Comparison of NICE guideline CG149 and the sepsis risk calculator for the management of early-onset sepsis on the postnatal ward","volume":"118","author":"Kimpton","year":"2021","journal-title":"Neonatology"},{"year":"","article-title":"Provisional Births in England and Wales: 2022","key":"B6"},{"year":"","article-title":"Recommendation 1.5: National Institute for Health and Care Excellence (NICE). Neonatal infection: antibiotics for prevention and treatment. NICE guideline [NG195]","key":"B7"},{"key":"B8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/ng0793-289","article-title":"Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness","volume":"4","author":"Prezant","year":"1993","journal-title":"Nat Genet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1001\/jamapediatrics.2022.0187","article-title":"Rapid point-of-care genotyping to avoid aminoglycoside-induced ototoxicity in neonatal intensive care","volume":"176","author":"McDermott","year":"2022","journal-title":"JAMA Pediatr"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e044457","DOI":"10.1136\/bmjopen-2020-044457","article-title":"Pharmacogenetics to avoid loss of hearing (PALOH) trial: a protocol for a prospective observational implementation trial","volume":"11","author":"McDermott","year":"2021","journal-title":"BMJ Open"},{"key":"B11","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1080\/14992027.2022.2155881","article-title":"Patient and public involvement in hearing research: opportunities, impact and reflections with case studies from the Manchester centre for audiology and deafness","volume":"63","author":"Dawes","year":"2024","journal-title":"Int J Audiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1136\/archdischild-2022-324331","article-title":"Cumulative risk factors contributing to hearing loss in preterm infants","volume":"108","author":"Chant","year":"2023","journal-title":"Arch Dis Childhood Fetal Neonat Ed"},{"key":"B13","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.ijporl.2014.02.015","article-title":"Normal hearing in a child with the m.1555A>G mutation despite repeated exposure to aminoglycosides. Has the penetrance of this pharmacogenetic interaction been overestimated?","volume":"78","author":"Al-Malky","year":"2014","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1086\/301676","article-title":"Familial progressive sensorineural deafness is mainly due to the mtDNA A1555G mutation and is enhanced by treatment with aminoglycosides","volume":"62","author":"Estivill","year":"1998","journal-title":"Am J Hum Genet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/1471-2431-14-210","article-title":"Mitochondrial mutation m.1555A>G as a risk factor for failed newborn hearing screening in a large cohort of preterm infants","volume":"14","author":"G\u00f6pel","year":"2014","journal-title":"BMC Pediatr"},{"key":"B16","first-page":"347","article-title":"Infant hearing loss: from diagnosis to therapy","volume":"32","author":"Paludetti","year":"2012","journal-title":"Acta Otorhinolaryngol Ital"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1471463\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T04:48:09Z","timestamp":1730177289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1471463\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":16,"alternative-id":["10.3389\/fped.2024.1471463"],"URL":"https:\/\/doi.org\/10.3389\/fped.2024.1471463","relation":{},"ISSN":["2296-2360"],"issn-type":[{"type":"electronic","value":"2296-2360"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"article-number":"1471463"}}